Press release
Now Available Global Pulmonary Arterial Hypertension Treatment Market Forecast And Growth 2016-2026
According to World Health Organization (WHO), raised blood pressure is estimated to cause 7.5 million deaths around the world. Hypertension is a risk factor for coronary heart disease, ischemic and hemorrhagic stroke. In addition complications of hypertension includes peripheral vascular disease, heart failure, renal impairment, retinal hemorrhage and visual impairment.Having family history of Pulmonary Arterial Hypertension, change in life style, unhealthy food, and physical inactivity causes hypertension.
To treat pulmonary atrial hypertension following treatments are available
Medication
Surgeries
Medications include blood vessel dilators (vasodilators), Endothelin receptor antagonists, phosphodiesterase III inhibitors, calcium channel blockers, anticoagulants, diuretics.
Atrial septostomy and Transplantation are the two surgery option for patients who suffering from severe pulmonary atrial hypertension. Transplantation is may be an option for younger people who are suffering from idiopathic pulmonary hypertension.
Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1218
Pulmonary Arterial Hypertension Treatment Market: Drivers and Restraints
According to World Health Organization, Globally the prevalence rate of hypertension was 40% in adults who aged 25 and above in the year 2008. The prevalence rate is high in Africa region and Americas having less prevalence rate in hypertension. Change in the life style, family history of pulmonary atrial hypertension, unhealthy food, and physical inactivity are the risk factors for hypertension as well as drivers for this market. Raising the geriatric population around the world also driver for pulmonary atrial hypertension treatment market. Guidelines form government organizations such as World Health Organization (WHO), Center for Disease Control and Prevention plays a major role in the prevention of pulmonary atrial hypertension treatment.
Pulmonary Arterial Hypertension Treatment Market: Segmentation
Pulmonary Arterial Hypertension Treatment Market is segmented into following types:
Based on Treatment
Medication
Blood Vessel Dilators (Vasodilators)
Endothelin Receptor Antagonists
Phosphodiesterase III Inhibitors
Calcium Channel Blockers
Anticoagulants
Diuretics
Based on End User
Hospital
Drug store
Hospital Pharmacies
Pulmonary Arterial Hypertension Treatment Market: Overview
With good awareness about healthcare among people and guidance from international organizations about the Pulmonary Arterial Hypertension Treatment, the market is expected to have a healthy growth in the forecast period (2016-2026)
Pulmonary Arterial Hypertension TreatmentMarket: Region- wise Outlook
Depending on geographic regions, the global Pulmonary Arterial Hypertension Treatment market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.
Pulmonary Arterial Hypertension Treatment is high in North America because it is highly developed region, having good healthcare setup and people are having good awareness about health care. Asia Pacific is expected to grow at a remarkable CAGR. Europe also having good growth in this market.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1218
Pulmonary Arterial Hypertension TreatmentMarket: Key Players
Some of the key players in this market are
Pfizer inc.
Bristol myers co
Novartis AG.
GlaxoSmithKline Pharmaceuticals Limited
Baxter
Dr. Reddy’s Laboratories Ltd.
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Now Available Global Pulmonary Arterial Hypertension Treatment Market Forecast And Growth 2016-2026 here
News-ID: 451395 • Views: …
More Releases from Future Market Insights
Eye Health Ingredients Market to Reach USD 360.3 Million by 2035, Driven by 7.5% …
The global eye health ingredients industry is projected to reach USD 360.3 million by 2035, expanding from USD 174.8 million in 2025 at a CAGR of 7.5%. Growth is fueled by increasing consumer awareness around preventive eye health, heavy screen exposure, and rising age-related vision issues. As consumers adopt nutraceuticals, fortified foods, and ocular supplements, demand for carotenoids, omega-based compounds, and botanical extracts continues to scale across retail and healthcare…
Global Grapeseed Oil Market Set for 4.1% CAGR, Expected to Hit USD 809.3 Million …
The global grapeseed oil market is projected to grow from USD 541.5 million in 2025 to USD 809.3 million by 2035, registering a CAGR of 4.1%. Rising demand across culinary, personal care, and nutraceutical applications is elevating its market value due to its rich antioxidant profile, vitamin E content, and plant-based origin.
Health-conscious consumers are increasingly choosing grapeseed oil for premium cooking and natural skincare, while manufacturers expand cold-pressing capacities to…
Soybean Enzymatic Protein Market Set to Reach USD 5.2 Billion by 2035, Driven by …
The global soybean enzymatic protein market is moving into a phase of rapid commercial adoption, projected to expand from USD 2.4 billion in 2025 to USD 5.2 billion by 2035, registering a CAGR of 7.8%. What began as a niche application segment during 2020-2024 has now matured into a scalable, mainstream protein category integrated into beverages, functional foods, meat alternatives, and nutritional supplements.
Between 2025 and 2030, the market enters its…
Global Squid Market to Reach USD 18.4 Billion by 2035, Driven by 3.8% CAGR Growt …
The global squid market, valued at USD 12.7 billion in 2025, is projected to reach USD 18.4 billion by 2035, reflecting a 3.8% CAGR, driven by rising seafood demand, diversified product formats, and robust food supply chains. Steady consumption growth across Asia-Pacific, Europe, and North America continues to uplift commercial fishing, aquaculture, and value-added squid processing.
Growth momentum between 2021 and 2025 shows a consistent upward curve, with the market expanding…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
